Over the past several decades, a number of studies have linked selective serotonin reuptake inhibitors (SSRIs) to a range of birth defects: neurological birth defects including spina bifida, cardiovascular birth defects including tricuspid atresia, craniofacial defects like cleft palate, developmental disorders such as autism, and neonatal adaptation disorders. As the manufacturers of many SSRIs have failed to notify expecting mothers of these risks, a number of SSRI birth defect lawsuits have been filed.
Here, I present another mention of this connection, published in a 2010 edition of Reproductive Toxicology by M. Effolk and H. Malm of Helsinki University Central Hospital (Finland). Their article is titled “Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).”
The team states “Prenatal exposure to selective serotonin reuptake inhibitors (SSRIs) may increase risk for congenital malformations and adverse perinatal outcome” and performed a literature review.
Results showed that “paroxetine and possibly fluoxetine use in early pregnancy may be associated with a small increased risk for cardiovascular malformations. Perinatal adverse effects, including respiratory distress and neonatal adaptation problems are common in exposed infants, and an increased risk for persistent pulmonary hypertension of the newborn (PPHN) has been observed.” These findings are largely in line with other similar research. To see more studies linking SSRIs and birth defects, follow the preceding link.
If you or a loved one used SSRIs and had a child who was born with a congenital malformation, developmental disorder, or who had a poor neonatal adaptation, you may be entitled to significant financial compensation. For a free, no-obligation case consultation, contact our team of SSRI birth defects lawyers at the information provided below. We have the experience, resources, and skills required to win the justice you deserve. Call today and see how we can help.
(855) 452 – 5529